Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05251727 · ClinicalTrials.gov registry record · Phase 1
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
A Phase 1 study, sponsored by Veloxis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT05251727 is a Phase 1 study that was terminated before completion, run by Veloxis Pharmaceuticals. The registered enrollment target is 77 participants.
The verdict
NCT05251727, a Phase 1 study, was terminated before completion, sponsored by Veloxis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
Interventions
- DRUG Placebo
- DRUG thrombomodulin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2024-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05251727
The ClinicalTrials.gov registry entry for NCT05251727 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veloxis Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05251727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05251727 about?
NCT05251727 is a clinical study titled "Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients". To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
What is the current status of trial NCT05251727?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2022-03-24. Estimated completion is 2024-06-05.
What interventions are being tested in trial NCT05251727?
The interventions under investigation include: Placebo (DRUG), thrombomodulin alfa (DRUG).
Who is sponsoring clinical trial NCT05251727?
This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.